CN1295217C - 用于制备二芳基甲基哌嗪衍生物的新不对称二芳基甲胺中间体 - Google Patents
用于制备二芳基甲基哌嗪衍生物的新不对称二芳基甲胺中间体 Download PDFInfo
- Publication number
- CN1295217C CN1295217C CNB2005100879382A CN200510087938A CN1295217C CN 1295217 C CN1295217 C CN 1295217C CN B2005100879382 A CNB2005100879382 A CN B2005100879382A CN 200510087938 A CN200510087938 A CN 200510087938A CN 1295217 C CN1295217 C CN 1295217C
- Authority
- CN
- China
- Prior art keywords
- general formula
- compound
- definition
- methyl
- obtains
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 238000000034 method Methods 0.000 title claims abstract description 20
- 238000002360 preparation method Methods 0.000 title claims abstract description 18
- 239000000543 intermediate Substances 0.000 title description 15
- 150000001875 compounds Chemical class 0.000 claims description 59
- -1 alkyl lithium Chemical compound 0.000 claims description 37
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 33
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 19
- 238000006243 chemical reaction Methods 0.000 claims description 15
- PIZNQHDTOZMVBH-UHFFFAOYSA-N thionylimide Chemical compound N=S=O PIZNQHDTOZMVBH-UHFFFAOYSA-N 0.000 claims description 12
- 239000003153 chemical reaction reagent Substances 0.000 claims description 10
- 229910052744 lithium Inorganic materials 0.000 claims description 6
- 238000010306 acid treatment Methods 0.000 claims description 5
- 150000004678 hydrides Chemical class 0.000 claims description 5
- 150000002576 ketones Chemical class 0.000 claims description 4
- QQIRAVWVGBTHMJ-UHFFFAOYSA-N [dimethyl-(trimethylsilylamino)silyl]methane;lithium Chemical compound [Li].C[Si](C)(C)N[Si](C)(C)C QQIRAVWVGBTHMJ-UHFFFAOYSA-N 0.000 claims description 3
- 125000002485 formyl group Chemical class [H]C(*)=O 0.000 claims 1
- 150000001412 amines Chemical class 0.000 abstract description 6
- 230000029936 alkylation Effects 0.000 abstract description 4
- 238000005804 alkylation reaction Methods 0.000 abstract description 4
- 238000011914 asymmetric synthesis Methods 0.000 abstract description 4
- 150000002902 organometallic compounds Chemical class 0.000 abstract description 3
- 125000004193 piperazinyl group Chemical group 0.000 abstract description 2
- 238000003786 synthesis reaction Methods 0.000 abstract description 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 238000003776 cleavage reaction Methods 0.000 abstract 1
- 230000007017 scission Effects 0.000 abstract 1
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 36
- 229910052757 nitrogen Inorganic materials 0.000 description 19
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 18
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 17
- 238000005481 NMR spectroscopy Methods 0.000 description 15
- 239000000460 chlorine Substances 0.000 description 13
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 10
- KXDAEFPNCMNJSK-UHFFFAOYSA-N Benzamide Chemical compound NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 description 10
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 9
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 9
- 229960001866 silicon dioxide Drugs 0.000 description 9
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 8
- 239000000377 silicon dioxide Substances 0.000 description 8
- 235000012239 silicon dioxide Nutrition 0.000 description 8
- 238000003756 stirring Methods 0.000 description 8
- 239000000203 mixture Substances 0.000 description 7
- BAVYZALUXZFZLV-UHFFFAOYSA-N mono-methylamine Natural products NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 7
- 238000000746 purification Methods 0.000 description 7
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 6
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Natural products C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 6
- RMVRSNDYEFQCLF-UHFFFAOYSA-N thiophenol Chemical compound SC1=CC=CC=C1 RMVRSNDYEFQCLF-UHFFFAOYSA-N 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 5
- 239000003513 alkali Substances 0.000 description 5
- 239000012141 concentrate Substances 0.000 description 5
- 238000002425 crystallisation Methods 0.000 description 5
- 230000008025 crystallization Effects 0.000 description 5
- SFQGDSLRVPLRJY-UHFFFAOYSA-N 3-(2-chloroethyl)-2-nitrobenzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=CC(CCCl)=C1[N+]([O-])=O SFQGDSLRVPLRJY-UHFFFAOYSA-N 0.000 description 4
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 4
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 4
- 125000000217 alkyl group Chemical group 0.000 description 4
- 229910052801 chlorine Inorganic materials 0.000 description 4
- 238000001704 evaporation Methods 0.000 description 4
- 230000008020 evaporation Effects 0.000 description 4
- 238000000605 extraction Methods 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 125000006239 protecting group Chemical group 0.000 description 4
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 3
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 3
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 3
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 3
- 229910052794 bromium Inorganic materials 0.000 description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 3
- 229910052731 fluorine Inorganic materials 0.000 description 3
- 239000011737 fluorine Substances 0.000 description 3
- 239000012442 inert solvent Substances 0.000 description 3
- 239000011630 iodine Substances 0.000 description 3
- 229910052740 iodine Inorganic materials 0.000 description 3
- 239000012071 phase Substances 0.000 description 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 3
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 3
- 239000012279 sodium borohydride Substances 0.000 description 3
- 229910000033 sodium borohydride Inorganic materials 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 description 3
- 125000001544 thienyl group Chemical group 0.000 description 3
- JMXKSZRRTHPKDL-UHFFFAOYSA-N titanium ethoxide Chemical compound [Ti+4].CC[O-].CC[O-].CC[O-].CC[O-] JMXKSZRRTHPKDL-UHFFFAOYSA-N 0.000 description 3
- 238000005160 1H NMR spectroscopy Methods 0.000 description 2
- HWTDMFJYBAURQR-UHFFFAOYSA-N 80-82-0 Chemical class OS(=O)(=O)C1=CC=CC=C1[N+]([O-])=O HWTDMFJYBAURQR-UHFFFAOYSA-N 0.000 description 2
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 2
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 2
- MKYBYDHXWVHEJW-UHFFFAOYSA-N N-[1-oxo-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propan-2-yl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(C(C)NC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 MKYBYDHXWVHEJW-UHFFFAOYSA-N 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 2
- 150000001408 amides Chemical class 0.000 description 2
- 150000003857 carboxamides Chemical class 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000004587 chromatography analysis Methods 0.000 description 2
- 238000011097 chromatography purification Methods 0.000 description 2
- 125000004122 cyclic group Chemical group 0.000 description 2
- 235000019439 ethyl acetate Nutrition 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- 125000002541 furyl group Chemical group 0.000 description 2
- 229910052736 halogen Inorganic materials 0.000 description 2
- 150000002367 halogens Chemical class 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 125000001072 heteroaryl group Chemical group 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 238000013507 mapping Methods 0.000 description 2
- WTVMYSTUHCTKBW-UHFFFAOYSA-N n,n-diethyl-4-(quinoline-8-carbonyl)benzamide Chemical compound C1=CC(C(=O)N(CC)CC)=CC=C1C(=O)C1=CC=CC2=CC=CN=C12 WTVMYSTUHCTKBW-UHFFFAOYSA-N 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Substances [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 235000015320 potassium carbonate Nutrition 0.000 description 2
- 125000004076 pyridyl group Chemical group 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 2
- 239000012321 sodium triacetoxyborohydride Substances 0.000 description 2
- 238000003797 solvolysis reaction Methods 0.000 description 2
- FIOJWGRGPONADF-UHFFFAOYSA-N (sulfinylamino)benzene Chemical compound O=S=NC1=CC=CC=C1 FIOJWGRGPONADF-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- FGDQTHASXFHXFV-UHFFFAOYSA-N C=O.O1C=C(C=C1)C(=O)O Chemical compound C=O.O1C=C(C=C1)C(=O)O FGDQTHASXFHXFV-UHFFFAOYSA-N 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 239000005864 Sulphur Substances 0.000 description 1
- RTAQQCXQSZGOHL-UHFFFAOYSA-N Titanium Chemical compound [Ti] RTAQQCXQSZGOHL-UHFFFAOYSA-N 0.000 description 1
- 239000003875 Wang resin Substances 0.000 description 1
- NERFNHBZJXXFGY-UHFFFAOYSA-N [4-[(4-methylphenyl)methoxy]phenyl]methanol Chemical compound C1=CC(C)=CC=C1COC1=CC=C(CO)C=C1 NERFNHBZJXXFGY-UHFFFAOYSA-N 0.000 description 1
- 150000001299 aldehydes Chemical class 0.000 description 1
- 230000003113 alkalizing effect Effects 0.000 description 1
- 125000004390 alkyl sulfonyl group Chemical group 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- SOCTUWSJJQCPFX-UHFFFAOYSA-N dichromate(2-) Chemical compound [O-][Cr](=O)(=O)O[Cr]([O-])(=O)=O SOCTUWSJJQCPFX-UHFFFAOYSA-N 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000000295 fuel oil Substances 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- RCBVKBFIWMOMHF-UHFFFAOYSA-L hydroxy-(hydroxy(dioxo)chromio)oxy-dioxochromium;pyridine Chemical compound C1=CC=NC=C1.C1=CC=NC=C1.O[Cr](=O)(=O)O[Cr](O)(=O)=O RCBVKBFIWMOMHF-UHFFFAOYSA-L 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 150000002466 imines Chemical class 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000012299 nitrogen atmosphere Substances 0.000 description 1
- 239000012434 nucleophilic reagent Substances 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 150000004885 piperazines Chemical class 0.000 description 1
- 239000002952 polymeric resin Substances 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- 239000012264 purified product Substances 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002194 synthesizing effect Effects 0.000 description 1
- 229920003002 synthetic resin Polymers 0.000 description 1
- 229940066771 systemic antihistamines piperazine derivative Drugs 0.000 description 1
- 150000003512 tertiary amines Chemical class 0.000 description 1
- CWERGRDVMFNCDR-UHFFFAOYSA-N thioglycolic acid Chemical compound OC(=O)CS CWERGRDVMFNCDR-UHFFFAOYSA-N 0.000 description 1
- 229910052719 titanium Inorganic materials 0.000 description 1
- 239000010936 titanium Substances 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 125000005490 tosylate group Chemical group 0.000 description 1
- 125000001425 triazolyl group Chemical group 0.000 description 1
- JBWKIWSBJXDJDT-UHFFFAOYSA-N triphenylmethyl chloride Chemical compound C=1C=CC=CC=1C(C=1C=CC=CC=1)(Cl)C1=CC=CC=C1 JBWKIWSBJXDJDT-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pain & Pain Management (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
- Quinoline Compounds (AREA)
- Furan Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE01007640 | 2001-03-07 | ||
| SE0100764A SE0100764D0 (sv) | 2001-03-07 | 2001-03-07 | New assymetric process |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB028060326A Division CN1244565C (zh) | 2001-03-07 | 2002-03-05 | 对于制备二芳基甲基哌嗪衍生物的新不对称方法和新不对称二芳基甲胺中间体 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN1721407A CN1721407A (zh) | 2006-01-18 |
| CN1295217C true CN1295217C (zh) | 2007-01-17 |
Family
ID=20283236
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB028060326A Expired - Fee Related CN1244565C (zh) | 2001-03-07 | 2002-03-05 | 对于制备二芳基甲基哌嗪衍生物的新不对称方法和新不对称二芳基甲胺中间体 |
| CNB2005100879382A Expired - Fee Related CN1295217C (zh) | 2001-03-07 | 2002-03-05 | 用于制备二芳基甲基哌嗪衍生物的新不对称二芳基甲胺中间体 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNB028060326A Expired - Fee Related CN1244565C (zh) | 2001-03-07 | 2002-03-05 | 对于制备二芳基甲基哌嗪衍生物的新不对称方法和新不对称二芳基甲胺中间体 |
Country Status (20)
| Country | Link |
|---|---|
| US (2) | US7045625B2 (enExample) |
| EP (1) | EP1368325B1 (enExample) |
| JP (1) | JP2004522793A (enExample) |
| KR (1) | KR100856996B1 (enExample) |
| CN (2) | CN1244565C (enExample) |
| AT (1) | ATE406354T1 (enExample) |
| BR (1) | BR0207817A (enExample) |
| CA (1) | CA2440104A1 (enExample) |
| DE (1) | DE60228548D1 (enExample) |
| DK (1) | DK1368325T3 (enExample) |
| ES (1) | ES2311050T3 (enExample) |
| IL (1) | IL157460A0 (enExample) |
| MX (1) | MXPA03007889A (enExample) |
| NO (1) | NO325156B1 (enExample) |
| NZ (1) | NZ527656A (enExample) |
| PT (1) | PT1368325E (enExample) |
| SE (1) | SE0100764D0 (enExample) |
| SI (1) | SI1368325T1 (enExample) |
| WO (1) | WO2002070492A1 (enExample) |
| ZA (1) | ZA200306448B (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114560781A (zh) * | 2022-03-01 | 2022-05-31 | 无锡捷化医药科技有限公司 | 一种n,n-二(2-氯乙基)-4-硝基苯基丙氨酸甲酯的制备方法 |
| CN114702457A (zh) * | 2022-03-30 | 2022-07-05 | 青岛科技大学 | 一种二芳基甲胺类化合物的绿色合成方法 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1997023466A1 (en) * | 1995-12-22 | 1997-07-03 | Astra Pharma Inc. | Novel compounds with analgesic effect |
| US5658908A (en) * | 1992-02-03 | 1997-08-19 | Delta Pharmaceuticals, Inc. | Opioid diarylmethylpiperazines and piperdines |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2149881T3 (es) * | 1993-07-30 | 2000-11-16 | Delta Pharmaceuticals Inc | Compuestos de piperazina usados en terapia. |
| SE9904673D0 (sv) * | 1999-12-20 | 1999-12-20 | Astra Pharma Inc | Novel compounds |
| SE0001209D0 (sv) | 2000-04-04 | 2000-04-04 | Astrazeneca Canada Inc | Novel compounds |
-
2001
- 2001-03-07 SE SE0100764A patent/SE0100764D0/xx unknown
-
2002
- 2002-03-05 NZ NZ527656A patent/NZ527656A/en unknown
- 2002-03-05 CN CNB028060326A patent/CN1244565C/zh not_active Expired - Fee Related
- 2002-03-05 PT PT02701852T patent/PT1368325E/pt unknown
- 2002-03-05 DE DE60228548T patent/DE60228548D1/de not_active Expired - Fee Related
- 2002-03-05 CA CA002440104A patent/CA2440104A1/en not_active Abandoned
- 2002-03-05 WO PCT/SE2002/000376 patent/WO2002070492A1/en not_active Ceased
- 2002-03-05 CN CNB2005100879382A patent/CN1295217C/zh not_active Expired - Fee Related
- 2002-03-05 ES ES02701852T patent/ES2311050T3/es not_active Expired - Lifetime
- 2002-03-05 JP JP2002569812A patent/JP2004522793A/ja active Pending
- 2002-03-05 IL IL15746002A patent/IL157460A0/xx unknown
- 2002-03-05 US US10/468,989 patent/US7045625B2/en not_active Expired - Fee Related
- 2002-03-05 MX MXPA03007889A patent/MXPA03007889A/es active IP Right Grant
- 2002-03-05 KR KR1020037011675A patent/KR100856996B1/ko not_active Expired - Fee Related
- 2002-03-05 SI SI200230739T patent/SI1368325T1/sl unknown
- 2002-03-05 AT AT02701852T patent/ATE406354T1/de not_active IP Right Cessation
- 2002-03-05 BR BR0207817-1A patent/BR0207817A/pt not_active IP Right Cessation
- 2002-03-05 EP EP02701852A patent/EP1368325B1/en not_active Expired - Lifetime
- 2002-03-05 DK DK02701852T patent/DK1368325T3/da active
-
2003
- 2003-08-19 ZA ZA200306448A patent/ZA200306448B/en unknown
- 2003-09-05 NO NO20033944A patent/NO325156B1/no not_active IP Right Cessation
-
2005
- 2005-11-22 US US11/285,672 patent/US7423154B2/en not_active Expired - Fee Related
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5658908A (en) * | 1992-02-03 | 1997-08-19 | Delta Pharmaceuticals, Inc. | Opioid diarylmethylpiperazines and piperdines |
| WO1997023466A1 (en) * | 1995-12-22 | 1997-07-03 | Astra Pharma Inc. | Novel compounds with analgesic effect |
| CN1209124A (zh) * | 1995-12-22 | 1999-02-24 | 阿斯特拉制药公司 | 新的具有止痛作用的化合物 |
Also Published As
| Publication number | Publication date |
|---|---|
| DE60228548D1 (de) | 2008-10-09 |
| ES2311050T3 (es) | 2009-02-01 |
| NO20033944L (no) | 2003-10-31 |
| NZ527656A (en) | 2005-04-29 |
| MXPA03007889A (es) | 2003-12-04 |
| WO2002070492A1 (en) | 2002-09-12 |
| PT1368325E (pt) | 2008-10-27 |
| ZA200306448B (en) | 2004-09-08 |
| SI1368325T1 (sl) | 2008-12-31 |
| US20060074238A1 (en) | 2006-04-06 |
| CN1721407A (zh) | 2006-01-18 |
| CN1494532A (zh) | 2004-05-05 |
| ATE406354T1 (de) | 2008-09-15 |
| EP1368325A1 (en) | 2003-12-10 |
| KR20030080075A (ko) | 2003-10-10 |
| NO325156B1 (no) | 2008-02-11 |
| JP2004522793A (ja) | 2004-07-29 |
| SE0100764D0 (sv) | 2001-03-07 |
| BR0207817A (pt) | 2004-03-09 |
| KR100856996B1 (ko) | 2008-09-04 |
| US7423154B2 (en) | 2008-09-09 |
| EP1368325B1 (en) | 2008-08-27 |
| IL157460A0 (en) | 2004-03-28 |
| US7045625B2 (en) | 2006-05-16 |
| CN1244565C (zh) | 2006-03-08 |
| US20040077861A1 (en) | 2004-04-22 |
| DK1368325T3 (da) | 2008-11-24 |
| CA2440104A1 (en) | 2002-09-12 |
| NO20033944D0 (no) | 2003-09-05 |
| HK1059436A1 (en) | 2004-07-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN1075718A (zh) | 金属醇盐 | |
| CN1305853C (zh) | Hmg辅酶a还原酶抑制剂的制备方法 | |
| CN1234679C (zh) | 3,3－二芳基丙基胺衍生物的简化合成法 | |
| CN1756734A (zh) | 谷氨酸衍生物和焦谷氨酸衍生物的制造方法和新型的制造用中间体 | |
| CN1218463A (zh) | 不对称合成R-α-丙基-胡椒基胺及其类似物的新方法 | |
| CN1072661C (zh) | 新的取代[2－(1－哌嗪基)乙氧基]甲基化合物 | |
| CN1835909A (zh) | 芳胺的制备方法 | |
| CN1225084A (zh) | 手性β－氨基酸的不对称合成 | |
| CN1308332C (zh) | 芳基醚的制备方法 | |
| CN1082046C (zh) | 2－(2－羟甲基苯基)乙酰胺衍生物的制备方法及其制备用中间体 | |
| CN1295217C (zh) | 用于制备二芳基甲基哌嗪衍生物的新不对称二芳基甲胺中间体 | |
| CN1216039A (zh) | 制备紫杉酚的方法 | |
| CN101054355A (zh) | 光学纯双亚磺酰胺化合物及其应用 | |
| CN1479714A (zh) | 旋光性胺衍生物及其合成方法 | |
| CN1102644A (zh) | 缩合吡啶型甲羟戊酸内酯中间体及其制备方法 | |
| CN1190966A (zh) | 人体免疫缺陷病毒(hiv)蛋白酶抑制剂的制备工艺 | |
| CN1199729A (zh) | 使用 唑啉制备氯酮的方法 | |
| CN1339432A (zh) | 取代苯化合物的制取方法 | |
| CN1123544A (zh) | 旋光的3-(1-(烷氨基))烷基吡咯烷 | |
| CN1684945A (zh) | 制备中间体的方法 | |
| CN1639172A (zh) | 用于不对称烯丙基化反应、羟醛反应、串联羟醛反应和烯丙基化反应的试剂 | |
| CN1829710A (zh) | 可用于制备某些抗菌n－甲酰基羟胺的中间体的制备方法 | |
| CN1709864A (zh) | 一种紫杉醇及其类似物侧链的合成方法 | |
| CN1337938A (zh) | 用于制备手性氨基酸的新方法 | |
| CN1162408C (zh) | 从四氢呋喃化合物制备噁唑啉化合物的方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20070117 Termination date: 20100305 |